4D Molecular Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
4D Molecular Therapeutics, Inc. (FDMT) reported Net Income (Loss) Available to Common Stockholders, Basic of -$72.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$72.94M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$68.76M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $19.40M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$56.88M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$140.11M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$160.87M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$100.84M.
- 4D Molecular Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was -$107.49M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$72.94M 10-Q · filed 2026-08-13 | -$141.70M 10-Q · filed 2026-08-13 | -$122.30M derived: sum of 3 quarters · filed 2026-08-13 | -$179.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$68.76M 10-Q · filed 2026-05-07 | -$49.36M derived: sum of 2 quarters · filed 2026-05-07 | -$106.24M derived: sum of 3 quarters · filed 2026-05-07 | -$160.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $19.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$37.48M derived: sum of 2 quarters · filed 2026-03-18 | -$92.14M derived: sum of 3 quarters · filed 2026-08-13 | -$140.11M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$56.88M 10-Q · filed 2025-11-10 | -$111.53M derived: sum of 2 quarters · filed 2026-08-13 | -$159.51M 10-Q · filed 2025-11-10 | -$209.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$54.66M 10-Q · filed 2026-08-13 | -$102.63M 10-Q · filed 2026-08-13 | -$152.30M derived: sum of 3 quarters · filed 2026-08-13 | -$196.14M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$47.97M 10-Q · filed 2026-05-07 | -$97.64M derived: sum of 2 quarters · filed 2026-05-07 | -$141.49M derived: sum of 3 quarters · filed 2026-05-07 | -$176.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$49.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$93.51M derived: sum of 2 quarters · filed 2026-03-18 | -$128.47M derived: sum of 3 quarters · filed 2026-03-18 | -$160.87M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$43.84M 10-Q · filed 2025-11-10 | -$78.80M derived: sum of 2 quarters · filed 2025-11-10 | -$111.20M 10-Q · filed 2025-11-10 | -$143.48M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$34.95M 10-Q · filed 2025-08-11 | -$67.35M 10-Q · filed 2025-08-11 | -$99.64M derived: sum of 3 quarters · filed 2025-08-11 | -$109.89M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$32.40M 10-Q · filed 2025-05-08 | -$64.68M derived: sum of 2 quarters · filed 2025-05-08 | -$74.94M derived: sum of 3 quarters · filed 2025-05-08 | -$104.56M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$32.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$42.54M derived: sum of 2 quarters · filed 2025-02-28 | -$72.16M derived: sum of 3 quarters · filed 2025-02-28 | -$100.84M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$10.26M 10-Q · filed 2024-11-13 | -$39.87M derived: sum of 2 quarters · filed 2024-11-13 | -$68.55M 10-Q · filed 2024-11-13 | -$95.93M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$29.62M 10-Q · filed 2024-08-08 | -$58.30M 10-Q · filed 2024-08-08 | -$85.68M derived: sum of 3 quarters · filed 2024-08-08 | -$111.37M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$28.68M 10-Q · filed 2024-05-09 | -$56.06M derived: sum of 2 quarters · filed 2024-05-09 | -$81.75M derived: sum of 3 quarters · filed 2024-05-09 | -$109.84M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$27.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$53.07M derived: sum of 2 quarters · filed 2024-02-29 | -$81.16M derived: sum of 3 quarters · filed 2024-02-29 | -$107.49M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$25.69M 10-Q · filed 2023-11-09 | -$53.78M derived: sum of 2 quarters · filed 2023-11-09 | -$80.11M 10-Q · filed 2023-11-09 | -$105.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$28.09M 10-Q · filed 2023-08-09 | -$54.42M 10-Q · filed 2023-08-09 | -$79.51M derived: sum of 3 quarters · filed 2023-08-09 | -$101.75M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$26.34M 10-Q · filed 2023-05-11 | -$51.42M derived: sum of 2 quarters · filed 2023-05-11 | -$73.66M derived: sum of 3 quarters · filed 2023-05-11 | -$81.25M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$25.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$47.32M derived: sum of 2 quarters · filed 2023-03-15 | -$54.91M derived: sum of 3 quarters · filed 2023-03-15 | -$71.32M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$22.24M 10-Q · filed 2022-11-08 | -$29.83M derived: sum of 2 quarters · filed 2022-11-08 | -$46.23M 10-Q · filed 2022-11-08 | -$66.78M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$7.59M 10-Q · filed 2022-08-11 | -$24.00M 10-Q · filed 2022-08-11 | -$44.54M derived: sum of 3 quarters · filed 2022-08-11 | -$52.38M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$16.41M 10-Q · filed 2022-05-12 | -$36.95M derived: sum of 2 quarters · filed 2022-05-12 | -$44.79M derived: sum of 3 quarters · filed 2022-05-12 | -$59.94M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$20.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$28.38M derived: sum of 2 quarters · filed 2022-03-28 | -$43.53M derived: sum of 3 quarters · filed 2022-03-28 | -$56.69M 10-K · filed 2022-03-28 |
| 2020-09-30 | -$7.83M 10-Q · filed 2021-11-10 | -$22.99M derived: sum of 2 quarters · filed 2021-11-10 | -$36.15M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$15.15M 10-Q · filed 2021-08-12 | -$28.31M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | -$13.16M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | -$49.31M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |